Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita

• Published in: Frontiers in medicine Vol. 8; p. 713312
• Main Authors: Zillikens, Hannah, Kasprick, Anika, Osterloh, Colin, Gross, Natalie, Radziewitz, Michael, Hass, Cindy, Hartmann, Veronika, Behnen-Härer, Martina, Ernst, Nancy, Boch, Katharina, Vidarsson, Gestur, Visser, Remco, Laskay, Tamás, Yu, Xinhua, Petersen, Frank, Ludwig, Ralf J., Bieber, Katja
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 07.09.2021
• Subjects: bullous skin diseases; immune-complex induced autoimmunity; Medicine; neutrophils; PI3K; signaling

Class I phosphoinositide 3-kinases (PI3K) have been implemented in pathogenesis of experimental epidermolysis bullosa acquisita (EBA), an autoimmune skin disease caused by type VII collagen (COL7) autoantibodies. Mechanistically, inhibition of specific PI3K isoforms, namely PI3Kβ or PI3Kδ, impaired...